These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 22929996)

  • 1. Structural insight into receptor-selectivity for lurasidone.
    Ichikawa O; Okazaki K; Nakahira H; Maruyama M; Nagata R; Tokuda K; Horisawa T; Yamazaki K
    Neurochem Int; 2012 Dec; 61(7):1133-43. PubMed ID: 22929996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity.
    Ishibashi T; Horisawa T; Tokuda K; Ishiyama T; Ogasa M; Tagashira R; Matsumoto K; Nishikawa H; Ueda Y; Toma S; Oki H; Tanno N; Saji I; Ito A; Ohno Y; Nakamura M
    J Pharmacol Exp Ther; 2010 Jul; 334(1):171-81. PubMed ID: 20404009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lurasidone: a new drug in development for schizophrenia.
    Meyer JM; Loebel AD; Schweizer E
    Expert Opin Investig Drugs; 2009 Nov; 18(11):1715-26. PubMed ID: 19780705
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Homology modeling and docking evaluation of aminergic G protein-coupled receptors.
    McRobb FM; Capuano B; Crosby IT; Chalmers DK; Yuriev E
    J Chem Inf Model; 2010 Apr; 50(4):626-37. PubMed ID: 20187660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Binding of lurasidone, a novel antipsychotic, to rat 5-HT7 receptor: analysis by [3H]SB-269970 autoradiography.
    Horisawa T; Ishiyama T; Ono M; Ishibashi T; Taiji M
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Jan; 40():132-7. PubMed ID: 23367506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of selective antagonists of serotonin 5-HT7 and 5-HT1A receptors on MK-801-induced impairment of learning and memory in the passive avoidance and Morris water maze tests in rats: mechanistic implications for the beneficial effects of the novel atypical antipsychotic lurasidone.
    Horisawa T; Ishibashi T; Nishikawa H; Enomoto T; Toma S; Ishiyama T; Taiji M
    Behav Brain Res; 2011 Jun; 220(1):83-90. PubMed ID: 21277905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 5-HT1A and 5-HT7 receptors contribute to lurasidone-induced dopamine efflux.
    Huang M; Horiguchi M; Felix AR; Meltzer HY
    Neuroreport; 2012 May; 23(7):436-40. PubMed ID: 22415605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protein-based virtual screening of chemical databases. II. Are homology models of G-Protein Coupled Receptors suitable targets?
    Bissantz C; Bernard P; Hibert M; Rognan D
    Proteins; 2003 Jan; 50(1):5-25. PubMed ID: 12471595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lurasidone (SM-13496), a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in the rat passive-avoidance test.
    Ishiyama T; Tokuda K; Ishibashi T; Ito A; Toma S; Ohno Y
    Eur J Pharmacol; 2007 Oct; 572(2-3):160-70. PubMed ID: 17662268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lurasidone: an atypical antipsychotic for schizophrenia.
    Risbood V; Lee JR; Roche-Desilets J; Fuller MA
    Ann Pharmacother; 2012; 46(7-8):1033-46. PubMed ID: 22828971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The preclinical profile of lurasidone: clinical relevance for the treatment of schizophrenia.
    Tarazi FI; Riva MA
    Expert Opin Drug Discov; 2013 Oct; 8(10):1297-307. PubMed ID: 23837554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial.
    Nakamura M; Ogasa M; Guarino J; Phillips D; Severs J; Cucchiaro J; Loebel A
    J Clin Psychiatry; 2009 Jun; 70(6):829-36. PubMed ID: 19497249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents.
    Campiani G; Butini S; Fattorusso C; Catalanotti B; Gemma S; Nacci V; Morelli E; Cagnotto A; Mereghetti I; Mennini T; Carli M; Minetti P; Di Cesare MA; Mastroianni D; Scafetta N; Galletti B; Stasi MA; Castorina M; Pacifici L; Vertechy M; Di Serio S; Ghirardi O; Tinti O; Carminati P
    J Med Chem; 2004 Jan; 47(1):143-57. PubMed ID: 14695828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Addressing selective polypharmacology of antipsychotic drugs targeting the bioaminergic receptors through receptor dynamic conformational ensembles.
    Selvam B; Porter SL; Tikhonova IG
    J Chem Inf Model; 2013 Jul; 53(7):1761-74. PubMed ID: 23789628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lurasidone for schizophrenia: a brief review of a new second-generation antipsychotic.
    Citrome L
    Clin Schizophr Relat Psychoses; 2011 Jan; 4(4):251-7. PubMed ID: 21177242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic.
    Citrome L
    Int J Clin Pract; 2011 Feb; 65(2):189-210. PubMed ID: 21129135
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contribution of a helix 5 locus to selectivity of hallucinogenic and nonhallucinogenic ligands for the human 5-hydroxytryptamine2A and 5-hydroxytryptamine2C receptors: direct and indirect effects on ligand affinity mediated by the same locus.
    Almaula N; Ebersole BJ; Ballesteros JA; Weinstein H; Sealfon SC
    Mol Pharmacol; 1996 Jul; 50(1):34-42. PubMed ID: 8700116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Homology model-assisted elucidation of binding sites in GPCRs.
    Levit A; Barak D; Behrens M; Meyerhof W; Niv MY
    Methods Mol Biol; 2012; 914():179-205. PubMed ID: 22976029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Position 5.46 of the serotonin 5-HT2A receptor contributes to a species-dependent variation for the 5-HT2C agonist (R)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol-6(2H)-one: impact on selectivity and toxicological evaluation.
    Miller KJ; Wu GY; Varnes JG; Levesque P; Li J; Li D; Robl JA; Rossi KA; Wacker DA
    Mol Pharmacol; 2009 Dec; 76(6):1211-9. PubMed ID: 19767451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comment on the potential utility of the new atypical antipsychotic lurasidone in the geriatric population.
    Guay DR
    Consult Pharm; 2011 Aug; 26(8):579-82. PubMed ID: 21840821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.